Financial News
Articles published by Genentech
![](https://mms.businesswire.com/media/20231009596392/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20231003446568/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20231001225894/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230904578230/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
September 06, 2023
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20230831268123/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
September 01, 2023
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20230822987765/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
August 23, 2023
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20230719545756/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230712019800/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230630080506/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230613097002/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230609005052/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230516005196/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230508005106/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
May 09, 2023
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20230425005057/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230424005241/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230416005009/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230416005008/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230413005028/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
April 13, 2023
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20230319005007/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230309005120/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230209005012/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230206005656/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230118005680/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20230105005343/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20221221005003/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20221221005002/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
December 21, 2022
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20221212005172/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20221212005169/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
December 11, 2022
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20221210005040/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20221113005114/en/1635600/4/genentech_day02_ditl_28798.2_flat_rgb_hi_%281%29.jpg)
Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease
November 14, 2022
From Genentech
Via Business Wire
Tickers
RHHBY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.